# Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

> **NCT00321984** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 947 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Dexlansoprazole MR
- **DRUG:** Dexlansoprazole MR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00321984
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 947 (ACTUAL)
- **Last updated:** 2011-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321984, "Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00321984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*